Previous reports have shown that active JAK2 contributes to T cell acute lymphoblastic leukaemia (T-ALL) development and that JAK inhibitors may be a potential treatment for T-ALL. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.